The Synaptic Bases of Mental Diseases
6 January 2022
By analysing the fluctuations of different cerebral states, neuroscientists at Synapsy have identified a new neurological marker for attention deficit disorder with or without hyperactivity. Adult diagnosis of attention deficit hyperactive disorder (ADHD) is based on inattention and impulsivity criteria. Read more…
23 November 2021
A team from NCCR-Synapsy has identified a common neurobiological signature of dysfunction in the brain circuits involved in regulating emotions in three clinically-distinct psychiatric illnesses. People suffering from attention-deficit hyperactivity disorder (ADHD), bipolar disorder or borderline personality disorder share a Read more…
27 May 2021
Neuroscientists at Synapsy have identified one of the mechanisms behind the antidepressant effect of lactate, a molecule produced by the body during exercise. Its key features – lactate, NADH and neurogenesis – will pave the way for new treatment possibilities. Read more…
9 March 2021
Study by members of Synapsy, the Swiss National Centre of Competence in Research in psychiatric disorders, explains why we make poor decisions after stress even when motivated by the prospect of reward. The ability to assess the costs and benefits Read more…
11 February 2021
Synapsy’s neuroscientists based at EPFL have identified a cell molecule that can regulate anxiety and prevent depression. Located at the crossroads of multiple cellular mechanisms, this molecule reconciles the great heterogeneity of scientific observations and paves the way for future Read more…
17 December 2020
We spoke with Charles Finsterwald, PhD, Chief Scientific Officer and co-founder of the start-up Gliapharm about his career path and his decision to switch from fundamental research to application. An interest in neuroscience After a bachelor in biology and a Read more…
According to WHO, more than 264 million people in the world suffer from depression, a disorder that has a major impact on all facets of the lives of those it affects. It became the first cause of invalidity in 2020. Read more…
Bipolar disorders affect some 2% of the population. Patients present a wide variety of clinical symptoms of which many can be especially handicapping. A new approach to find biomarkers, driven by Pascal Jourdain, could change the game by improving treatment Read more…
Pierre Marquet’s career path has been rather untypical. Combining qualifications in physics and psychiatry-psychotherapy, he is a clinical researcher “par excellence”, engaged for over 20 years in the development of knowledge about the biological dimensions of mental disorders. His career Read more…
